Congenital Heart Disease Clinical Trial
Official title:
The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome
The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease.
Congenital heart disease (CHD) is the most common class of birth defect and is a major cause
of infant and child death and morbidity, including neurodevelopmental delay. Children with
severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that
include learning disability, attention deficit and hyperactivity disorder, behavioral
problems and mental retardation. The etiology of neurodevelopmental delay in children with
CHD is not fully understood but is thought to be secondary to a combination of pre- and
post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD
have abnormal blood flow to the brain as measured by Doppler ultrasound. This
"centralization" or redirection of blood flow toward vital organs such as the brain has been
shown to lead to abnormal brain development in other fetal diseases, such as intrauterine
growth restriction. Evidence of the importance of prenatal brain development in the setting
of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure
and blood flow prior to cardiothoracic surgery. However, to date, associations between
abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not
been established in the CHD population. Finally, newborns with CHD have been shown to have
abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic
nervous system, which controls heart rate and blood pressure, may not function properly in
infants with CHD.
The study proposes that these changes in blood flows in the fetus with heart disease could be
responsible in part for poor brain growth, abnormal brain structure and function and
developmental delay in childhood. Investigators will use routine obstetrical ultrasound and
fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with
CHD. Investigators will use non-invasive fetal monitors to measure fetal heart rate and
movement. Investigators will look at brain structure using Magnetic Resonance Imaging (MRI)
in the fetus and newborn. Afterbirth, investigators will use non-invasive monitors to measure
neonatal heart rate and blood pressure changes in response to a tilt, similar to what is
experienced when placing an infant in a car seat. Investigators will use a non-invasive
monitor consisting of a sticker applied to the skin to measure the level of oxygen in the
brain. Investigators will also measure brain function in the newborn with an
electroencephalogram(EEG) that records the electrical signaling between different parts of
the brain using a special plastic hat like a swim cap. Regular physical exams with a
pediatrician to measure growth and development will take place. A special test designed to
detect learning disabilities will also be done when the child is 14 months old. This test
will consist of talking with the child, reading stories, and showing the child pictures and
colors. There will be no extra blood tests needed and none of the tests pose any risk to the
mother, fetus, infant, or child.
The possible benefits to the child and the family will be early identification of any brain
abnormality in the newborn period as well as learning disabilities in the toddler which will
then allow the child to receive therapies designed to treat these problems. Studies show that
early identification and treatment of learning disabilities are important to enhance the
potential of the child.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04992793 -
Paediatric Brain Injury Following Cardiac Interventions
|
||
Recruiting |
NCT05213598 -
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
|
||
Completed |
NCT04136379 -
Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
|
||
Completed |
NCT04814888 -
3D Airway Model for Pediatric Patients
|
||
Recruiting |
NCT04920643 -
High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery
|
N/A | |
Completed |
NCT05934578 -
Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training
|
N/A | |
Recruiting |
NCT06041685 -
Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia
|
N/A | |
Recruiting |
NCT05902013 -
Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation
|
N/A | |
Not yet recruiting |
NCT05687292 -
Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
|
||
Not yet recruiting |
NCT05524324 -
Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT
|
N/A | |
Completed |
NCT02746029 -
Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
|
||
Completed |
NCT03119090 -
Fontan Imaging Biomarkers (FIB) Study
|
||
Completed |
NCT02537392 -
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
|
N/A | |
Recruiting |
NCT02258724 -
Swiss National Registry of Grown up Congenital Heart Disease Patients
|
||
Completed |
NCT01966237 -
Milrinone Pharmacokinetics and Acute Kidney Injury
|
||
Terminated |
NCT02046135 -
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
|
Phase 2 | |
Recruiting |
NCT01184404 -
Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery
|
N/A | |
Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A |